ADVA
12.1.2021 09:02:30 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced the expansion of its Ensemble Harmony Ecosystem to include disaggregated packet networking. Alpha Networks, Delta, Edgecore Networks and UfiSpace have all joined the open multi-vendor program. Each new member offers high-performance hardware platforms proven to interoperate with ADVA’s Ensemble Activator, a carrier-grade network operating system (NOS) specifically designed for white box switches. The Ensemble Harmony Ecosystem helps to accelerate softwarization and virtualization by offering service providers and enterprises access to the industry’s most comprehensive portfolio of flexible and disaggregated networking technologies. The addition of white box switch suppliers means it now delivers even more value to customers and helps to further simplify their transition to software-driven networking.
“Since the inception of NFV, our Ensemble Harmony Ecosystem has led the way, delivering unparalleled variety and choice of onboarded virtual network functions (VNFs). Now we’re opening up this unique multi-vendor environment to include some of the industry’s most innovative hardware suppliers, ensuring easy interoperability and new levels of collaboration for the rapid development of future services,” said James Buchanan, GM, Edge Cloud, ADVA. “This latest expansion of Ensemble Harmony will help more customers to realize the true value of virtualization and disaggregated packet networking as a catalyst to openness, componentized systems and innovation at the speed of software. The journey to white box switches and servers and software-driven networking is now simpler and more cost-efficient than ever before. ADVA is now the clear leader in network operating systems for white boxes.”
With the addition of leading hardware suppliers, ADVA’s open Ensemble Harmony Ecosystem provides everything service providers and businesses require to harness the power of disaggregated networking. Each of the new member companies offers highly efficient white box technology proven to interoperate successfully with ADVA’s Ensemble Activator , the first NOS designed for bare-metal switches. Already successful in trials with multiple global mobile network operators, including Telefónica and Vodafone, Ensemble Activator is the market’s most versatile operating system for disaggregated cell site gateways. When combined with Ensemble Harmony partner hardware, it offers new levels of agility and freedom and a clear route to cost-effective mass rollout of 5G services over large, geographically dispersed, multi-vendor networks.
“We’re excited to be among the first hardware partners to be welcomed into the Ensemble Harmony Ecosystem. It’s a community that shares our dedication to openness and interoperability. Together we can remove even more of the shackles of single-vendor proprietary solutions,” commented George Tchaparian, CEO, Edgecore Networks. “Today’s customers refuse to accept the constraints, the complexity and the expense of closed hardware and software systems. They demand the freedom to build scalable, cost-effective infrastructure on best-in-class open products and solutions. That’s why we’re working closely with Ensemble Harmony software partners, helping operators make the leap to virtualization and harness the benefits of openness and disaggregation.”
“ADVA’s Ensemble Harmony Ecosystem is a pillar of the open environment. Its philosophy is perfectly aligned with our own focus on disaggregation and open networking. What’s more, by collaborating with ADVA, we can add more value to our innovations and increase speed to market for our customers,” said Vincent Ho, CEO, UfiSpace. “We’ve been driving the next generation of open networking solutions with our carrier-grade disaggregated white box and network cloud solutions. Now, as part of Ensemble Harmony, we can give even more customers the freedom to choose from a wide range of fully integrated software and hardware technologies and select the ideal disaggregated solution for their business needs.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005057/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom